Expression and alterations of the PTEN/AKT/mTOR pathway in ameloblastomas

Oral Diseases

Volumn 14, Issue 6, 2008, Pages 561-568

  Scheper, M A ^a,b   Chaisuparat, R ^b   Nikitakis, N G ^c   Sauk, J J ^b,d  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

Ameloblastoma; Dental follicle; Extracellular signal regulated kinase; p70 ribosomal subunit 6 kinase; Phosphatase and tensin homologue; Protein kinase B

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN P70; RIBOSOMAL SUBUNIT 6 KINASE; SERINE; THREONINE;

ADOLESCENT; ADULT; AGED; AMELOBLASTOMA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMELOBLASTOMA; CELL PROLIFERATION; DENTAL SAC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GINGIVAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MANDIBULAR NEOPLASMS; MAXILLARY NEOPLASMS; MIDDLE AGED; PHOSPHORYLATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TOOTH, IMPACTED; UP-REGULATION; YOUNG ADULT;

EID: 49749085585     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2007.01421.x     Document Type: Article

References (38)

1. Bello IO, Soini Y, Slootweg PJ, Salo T (2007). Claudins 1, 4, 5, 7 and occludin in ameloblastomas and developing human teeth. J Oral Pathol Med 36 : 48 54.
2. Bjornsti MA, Houghton PJ (2004). The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4 : 335 348.
3. Buchner A, Merrell PW, Carpenter WM (2006). Relative frequency of central odontogenic tumors: a study of 1,088 cases from Northern California and comparison to studies from other parts of the world. J Oral Maxillofac Surg 64 : 1343 1352.
4. Cantley LC, Neel BG (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96 : 4240 4245.
5. Carlson ER, Marx RE (2006). The ameloblastoma: primary, curative surgical management. J Oral Maxillofac Surg 64 : 484 494.
6. Chambard JC, Lefloch R, Pouyssegur J, Lenormand P (2006). ERK implication in cell cycle regulation. Biochim Biophys Acta 17 : 1299 1310.
7. Dillon RL, White DE, Muller WJ (2007). The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26 : 1338 1345.
8. Ghandhi D, Ayoub AF, Pogrel MA, MacDonald G, Brocklebank LM, Moos KF (2006). Ameloblastoma: a surgeon's dilemma. J Oral Maxillofac Surg 64 : 1010 1014.
9. Hay N (2005). The AKT-mTOR tango and its relevance to cancer. Cancer Cell 8 : 179 183.
10. Hendarmin L, Sandra F, Nakao Y, Ohishi M, Nakamura N (2005). TNFalpha played a role in induction of AKT and MAPK signals in ameloblastoma. Oral Oncol 41 : 375 382.
11. Inoki K, Corradetti MN, Guan KL (2005). Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37 : 19 24.
12. Kolch W (2000). Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351 : 289 305.
13. Kumamoto H, Ooya K (2005). Detection of mitochondria-mediated apoptosis signaling molecules in ameloblastomas. J Oral Pathol Med 34 : 565 572.
14. Kumamoto H, Ooya K (2006a). Immunohistochemical detection of MT1-MMP, RECK, and EMMPRIN in ameloblastic tumors. J Oral Pathol Med 35 : 345 351.
15. Kumamoto H, Ooya K (2006b). Immunohistochemical detection of platelet-derived endothelial cell growth factor/thymidine phosphorylase and angiopoietins in ameloblastic tumors. J Oral Pathol Med 35 : 606 612.
16. Kumamoto H, Ooya K (2006c). Immunohistochemical detection of retinoblastoma protein and E2 promoter-binding factor-1 in ameloblastomas. J Oral Pathol Med 35 : 183 189.
17. Kumamoto H, Ooya K (2007). Immunohistochemical detection of insulin-like growth factors, platelet-derived growth factor, and their receptors in ameloblastic tumors. J Oral Pathol Med 36 : 198 206.
18. Ladeinde AL, Ogunlewe MO, Bamgbose BO et al (2006). Ameloblastoma: analysis of 207 cases in a Nigerian teaching hospital. Quintessence Int 37 : 69 74.
19. Luo HY, Yu SF, Li TJ (2006). Differential expression of apoptosis-related proteins in various cellular components of ameloblastomas. Int J Oral Maxillofac Surg 35 : 750 755.
20. Neville BW, Damm DD, Allen CM, Bouquot JE (2002). Oral and maxillofacial pathology. W.B. Saunders company : Philadelphia, pp. 611 619.
21. Nodit L, Barnes L, Childers E, Finkelstein S, Swalsky P, Hunt J (2004). Allelic loss of tumor suppressor genes in ameloblastic tumors. Mod Pathol 17 : 1062 1067.
22. Reichart PA, Philipsen HP, Sonner S (1995). Ameloblastoma: biological profile of 3677 cases. Eur J Cancer B Oral Oncol 31 : 86 99.
23. Sandra F, Harada H, Nakamura N, Ohishi M (2004). Midkine induced growth of ameloblastoma through MAPK and AKT pathways. Oral Oncol 40 : 274 280.
24. Sandra F, Hendarmin L, Nakao Y, Nakamura N, Nakamura S (2005). TRAIL cleaves caspase-8, -9 and -3 of AM-1 cells: a possible pathway for TRAIL to induce apoptosis in ameloblastoma. Tumour Biol 26 : 258 264.
25. Sandra F, Hendarmin L, Nakamura S (2006a). Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol 42 : 415 420.
26. Sandra F, Hendarmin L, Nakao Y, Nakamura N, Nakamura S (2006b). Inhibition of AKT and MAPK pathways elevated potential of TNFalpha in inducing apoptosis in ameloblastoma. Oral Oncol 42 : 39 45.
27. Scheper MA, Nikitakis NG, Sarlani E, Sauk JJ, Meiller TF (2006). Cowden syndrome: report of a case with immunohistochemical analysis and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101 : 625 631.
28. Shah OJ, Wang Z, Hunter T (2004). Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14 : 1650 1656.
29. Shaw RJ, Cantley LC (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 : 424 430.
30. Shin KH, Kim JM, Rho KS, Park KH, Oh JE, Min BM (2002). Inactivation of the PTEN gene by mutation, exonic deletion, and loss of transcript in human oral squamous cell carcinomas. Int J Oncol 21 : 997 1001.
31. Song G, Ouyang G, Bao S (2005). The activation of AKT/PKB signaling pathway and cell survival. J Cell Mol Med 9 : 59 71.
32. Souza Andrade ES, da Costa Miguel MC, Pinto LP, de Souza LB (2007). Ameloblastoma and adenomatoid odontogenic tumor: the role of alpha2beta1, alpha3beta1, and alpha5beta1 integrins in local invasiveness and architectural characteristics. Ann Diagn Pathol 11 : 199 205.
33. Squarize CH, Castilho RM, Santos Pinto D Jr. (2002). Immunohistochemical evidence of PTEN in oral squamous cell carcinoma and its correlation with the histological malignancy grading system. J Oral Pathol Med 31 : 379 384.
34. Usami Y, Ito A, Ohnuma K, Fuku T, Komori T, Yokozaki H (2007). Tumor suppressor in lung cancer-1 as a novel ameloblast adhesion molecule and its downregulation in ameloblastoma. Pathol Int 57 : 68 75.
35. Vivanco I, Sawyers CL (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2 : 489 501.
36. Zhang B, Huang HZ, Tao Q, Liu XQ, Wei J (2006). Association of matrix metalloproteinase-2 activity with cell proliferation and growth in ameloblastoma. Hua Xi Kou Qiang Yi Xue Za Zhi 24 : 7 10.
37. Zhong M, Liu JD, Wang J et al (2006a). Expression and significance of hTERT, c-fos and c-jun in ameloblastoma. Shanghai Kou Qiang Yi Xue 15 : 461 465.
38. Zhong M, Wu L, Wang J, Zhang B, Hou L (2006b). Expression of cyclin D1 and its inhibitors and hTERT in ameloblastoma. Hua Xi Kou Qiang Yi Xue Za Zhi 24 : 495 498.